Real-world direct healthcare costs of treating recurrent high-grade serous ovarian cancer with cytotoxic chemotherapy

被引：4

作者：

Gilbert, Lucy ^{[1
,2
,3
]}

Ramanakumar, Agnihotram, V ^{[4
]}

Festa, Maria Carolina ^{[1
,2
]}

Jardon, Kris ^{[1
,2
,3
]}

Zeng, Xing ^{[1
,2
,3
]}

Martins, Claudia ^{[1
,2
,3
]}

Shbat, Layla ^{[1
,2
]}

Alsoud, Marwa Abo ^{[1
,2
]}

Borod, Manuel ^{[3
,5
]}

Wolfson, Michael ^{[6
]}

Papaioannou, Ioanna ^{[7
]}

Basso, Olga ^{[4
,8
]}

Sampalis, John ^{[7
,9
]}

机构：

[1] McGill Univ, Gynecol Canc Serv, Hlth Ctr, Canc Care Mission, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[2] McGill Univ, Dept Obstet & Gynecol, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[3] McGill Univ, Dept Oncol, 5100 Maisonneuve Blvd West, Montreal, PQ H4A 3T2, Canada

[4] McGill Univ, Res Inst, Hlth Ctr, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[5] McGill Univ, Support & Palliat Care Serv, Hlth Ctr, Canc Care Mission, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada

[6] Univ Ottawa, Dept Epidemiol & Community Med, 600 Peter Morand Crescent, Ottawa, ON K1G 5Z3, Canada

[7] JSS Med Res, 9400 Henri Bourassa West, Montreal, PQ H4S 1N8, Canada

[8] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, 1020 Pine Ave West, Montreal, PQ H3A 1A2, Canada

[9] McGill Univ, Fac Med, Dept Surg, Div Surg Res, 1650 Cedar Ave, Montreal, PQ H3G 1A4, Canada

来源：

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2020年 / 9卷 / 08期

关键词：

cytotoxic chemotherapy; healthcare costs; recurrent high-grade serous ovarian cancer; MAINTENANCE THERAPY; DOUBLE-BLIND; SURVIVAL; CARCINOMA; OUTCOMES; WOMEN;

D O I：

10.2217/cer-2020-0032

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

Aim: To describe the direct healthcare costs associated with repeated cytotoxic chemotherapy treatments for recurrent high-grade serous cancer (HGSC) of the ovaries. Patients & methods: Retrospective review of 66 women with recurrent stage III/IV HGSC ovarian cancer treated with repeated lines of cytotoxic chemotherapy in a Canadian University Tertiary Center. Results: Mean cost of treatment of first relapse was CAD$52,227 increasing by 38% for two, and 86% for three or more relapses with median overall survival of 36.0, 50.7 and 42.8 months, respectively. In-hospital care accounted for 71% and chemotherapy drugs accounted for 17% of the total costs. Conclusion: After the third relapse of HGSC, cytotoxic chemotherapy did not prolong survival but was associated with substantially increased healthcare costs.

引用

页码：537 / 551

页数：15

共 50 条

[1] Management of the Elderly Patients with High-Grade Serous Ovarian Cancer in the REAL-WORLD Setting
Liontos, Michalis
Papatheodoridi, Alkistis
Andrikopoulou, Angeliki
Thomakos, Nikolaus
Haidopoulos, Dimitrios
Rodolakis, Alexandros
Zagouri, Flora
Bamias, Aristotelis
Dimopoulos, Meletios-Athanasios
CURRENT ONCOLOGY, 2021, 28 (02) : 1143 - 1152
[2] Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients
Moya-Alarcon, Carlota
Piera, Guiomar
Callejo, Angel
Gasco, Amaya
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 11 (01) : 13 - 27
[3] Real-world transcriptomic investigation of primary to recurrent high-grade serous ovarian cancer (HGSOC) using bioinformatics analysis
Kim, Jae-Hoon
Chung, Dawn
Nam, Jo-Hyeon
Choi, Min Chul
Kim, H. Y. O. S. U. N.
Cho, Hanbyoul
Han, Mi-Ryung
GYNECOLOGIC ONCOLOGY, 2023, 176 : S322 - S322
[4] Real-world usage of NGS testing in high-grade serous ovarian cancer (HGSOC)-the landscape is quickly changing.
Goel, Nidhi
Londono, Angelina I.
Farrukh, Naveed
Beer, Hannah M.
Roane, Brandon
Arquiette, Jaclyn
Huh, Warner K.
Leath, Charles A., III
Arend, Rebecca C.
CLINICAL CANCER RESEARCH, 2020, 26 (13) : 38 - 39
[5] Immunotherapy that improves response to chemotherapy in high-grade serous ovarian cancer
Elorbany, Samar
Berlato, Chiara
Carnevalli, Larissa S.
Maniati, Eleni
Barry, Simon T.
Wang, Jun
Manchanda, Ranjit
Kzhyshkowska, Julia
Balkwill, Frances
NATURE COMMUNICATIONS, 2024, 15 (01)
[6] Real-world experience of olaparib maintenance in high grade serous recurrent ovarian cancer patients with BRCA 1/2 mutation
Paik, E. S.
Kim, J.
Kim, T-J.
Choi, C. H.
Lee, J-W.
Bae, D-S.
Kim, B-G.
ANNALS OF ONCOLOGY, 2018, 29 : 84 - 84
[7] Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
Paik, E. Sun
Lee, Yong Jae
Lee, Jung-Yun
Shin, Wonkyo
Park, Sang-Yoon
Kim, Se Ik
Kim, Jae-Weon
Choi, Chel Hun
Kim, Byoung-Gie
JOURNAL OF CLINICAL MEDICINE, 2019, 8 (11)
[8] Characterizing recurrent high-grade serous ovarian cancer through wholegenome sequencing
Christie, Elizabeth L.
Pattnaik, Swetansu
Fereday, Sian
Thorne, Heather
Bild, Andrea
Bowtell, David D.
CANCER RESEARCH, 2018, 78 (13)
[9] Recurrent gene fusions are common in high-grade serous ovarian cancer.
Lehtonen, Rainer
Carpen, Olli
Huhtinen, Kaisa
Hynninen, Johanna
Kaipio, Katja
Lamminen, Tarja
Cervera, Alejandra
Hietanen, Sakari
Grenman, Seija
Hautaniemi, Sampsa
CLINICAL CANCER RESEARCH, 2018, 24 (15) : 108 - 108
[10] Acquired chemotherapy resistance in high-grade serous ovarian cancer patients.
Christie, Elizabeth L.
Beach, Jessica
Etemadmoghadam, Dariush
Garsed, Dale
Patch, Ann-Marie
Fereday, Sian
Pattnaik, Swetansu
Brady, Samuel
Bild, Andrea
Bowtell, David D. L.
CLINICAL CANCER RESEARCH, 2018, 24 (15) : 20 - 20

← 1 2 3 4 5 →